Theranos Revenue, Valuation, Funding & Investors

electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.

Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.

iNtRON Biotechnology Inc is a Korea-based company principally engaged in the biotechnology industry. It develops, manufactures, and commercializes drugs for the treatment of infectious diseases. It is contributing to national health and national prevention through several (molecular) diagnostic products such as swine flu, VRE super bacteria, food poisoning, avian influenza and foot, and mouth disease. In addition, it is also engaged in the operation of a veterinary antibiotic alternative business and new biopharmaceuticals development business.

Identifai Genetics Ltd is engaged in the development, validation and commercial deployment of Windrose, a genome-wide non-invasiveprenatal screening platform. The Group's primary focus at this stage is completing CLIA registration and the analytical validation of Windrose, advancing its U.S. multicentre clinical validity study, and preparing for commercial launch in collaboration with Inocras. The Group's product, Windrose, is a first-trimesternon-invasive prenatal test that provides cfDNA-based fetal risk assessment.

Abingdon Health PLC develops, manufactures, and distributes diagnostic devices and provides regulatory consultancy to diagnostics businesses. It offers integrated lateral flow CRO/CDMO services covering feasibility, manufacturing, packaging, kitting, documentation, and commercial support. Segments include Contract Development (milestone-based third-party work, revenue over time by completion), Contract Manufacturing (development/manufacturing via daily consultancy, revenue at customer control point), Product Sales (AbC-19TM, Pocket Diagnostic, PCRD tests, research antibodies, carriage; point in time), and Regulatory Services (IVD/medical device compliance, revenue over time), with key revenue from Regulatory Services. It operates in the UK, USA/Canada, Europe, and rest of world.

Osang Healthcare Co Ltd is engaged in medical device development. It develops diagnostic biosensors for blood glucose measurement, HbA1c and cholesterol , Immuno Diagnosis, Molecular Diagnosis, etc.

GC Medical Science Corp is engaged in the manufacturing of medical supplies and related other medications. The company has developed and distributed a variety of sophisticated reagents to medical institutions in Korea and international markets around the world, including the U.S., Russia, Europe, Africa, Middle East, and India. Its reagents include infectious diseases (HIV, HBV, HCV etc.) test reagents, and tumor marker and parasitological test reagents.

Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services. The Company operates in two geographical regions, the United States and Australia and the majority of revenue is generated from the United States.

IMBdx Inc detects and analyzes the genomic profile of tumor DNA with a single draw of blood. It provides personalized and optimized analysis information that can be utilized in therapy selection and monitoring. Its AlphaLiquid platform offers ctDNA-based precision diagnostics solutions across the full continuum of cancer care, from therapy selection (AlphaLiquid 100/HRR) to recurrence and minimal residual disease(MRD) monitoring (CancerDetect), and multi-cancer early detection (CancerFind). Its services are Clinical Service BioPharma, Research, and Healthcare Checkup.

Genematrix Inc is a biotech company engaged in the development of the platform and molecular diagnostics products. Its products include NeoPlexTM STI-7 Detection kit, OmniPlex-HPV, PapilloTyper, HepB Typer-Adefovir, and HepB Typer-Precore among others.

Microba Life Sciences is an Australian precision microbiome company based in Brisbane that sells clinical gut microbiome tests and supplements and holds a pipeline of microbiome-based therapeutic candidates. It was founded in 2017 as a University of Queensland spin-out by Professors Gene Tyson and Philip Hugenholtz and listed on the Australian Securities Exchange on 5 April 2022. Its main product, MetaXplore, is a gastrointestinal test sold to clinicians in Australia and the United Kingdom, where it bought the Invivo Healthcare testing and supplements business in December 2023. Group revenue was A$15.7 million in the year to June 2025, up 30 per cent, and the net loss was A$14.9 million. Sonic Healthcare is its largest shareholder and a distribution partner for its tests. Microba transferred its research services unit to Clinical Microbiomics in late 2024 and paused internal research and development in the 2025 financial year to look for partners for its therapeutic assets. In 2026 it agreed commercial terms for a proposed all-scrip merger with Genetic Signatures.

Bionano Genomics is a San Diego life-sciences tools company founded in 2007 and listed on Nasdaq under BNGO. It develops optical genome mapping instruments, consumables and software used to detect structural genomic variation. Research laboratories, hospitals and pharmaceutical customers use its Saphyr platform and related informatics in cytogenetics and translational research. Revenue comes from instrument and consumable sales, software and laboratory services. Bionano expanded into genetic testing through the 2020 acquisition of Lineagen. It added BioDiscovery's NxClinical informatics platform in 2021 and Purigen's Ionic Purification System in 2022. These acquisitions broadened the company from a single instrument platform into an end-to-end genome analysis workflow. It remains the public operating company at bionano.com.

Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. The Group operates predominantly in one business segment, the research and development of cancer diagnostics, and two geographical segments, Victoria, Australia, and the United States of America, with the majority of revenue coming from Australia.

EZZ Life Science Holdings Ltd is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papillomavirus (HPV), helicobacter pylori, and weight management. The company is engaged in formulation, production, marketing and sale of the EZZ branded health and wellbeing products to retailers and consumers domestically and internationally, and wholesale distribution of the EAORON branded skin care products to retailers in Australia and New Zealand.